Top 5 Tech Stocks To Invest In Right Now

According to a recent report from Research and Markets, the global genetic testing market is estimated to grow from $4.6 billion in 2017 to $5.8 billion in 2022 at a CAGR of 11.7% driven by an aging global population, rising incidences of genetic and hereditary diseases, growing awareness, technological advancements and rise in application of genetic testing for early detection of various diseases. A major player and Billion-Dollar Unicorn in this market is 23andMe (Private:DNA).

23andMe’s Journey

Mountain View, California-based 23andMe was founded in 2006 by Chief Executive Anne Wojcicki, Linda Avey, and Paul Cusenza to help people access and benefit from human genome. It first introduced a service that allowed people to get their saliva samples analyzed for genetic markers that influence disease risk and medication response. People also could use the service to know about their ancestry.

The company was stuck in a complex web of regulations which culminated in the US Food and Drug Administration ordering the company to stop selling its personal genomics health tests in 2013.

Top 5 Tech Stocks To Invest In Right Now: Cray Inc(CRAY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the technology sector proved to be a source of strength for the market. Leading the sector was strength from Cray Inc. (NASDAQ: CRAY) and Mellanox Technologies, Ltd. (NASDAQ: MLNX).

  • [By Jim Robertson]

    Cray Inc. (CRAY) has been one of those feast or famine small caps that have either made traders and investors a lot of money in recent years – or simply frustrated those who’ve held it for quite some time. However, at this point we think CRAY offers an attractive risk/reward opportunity on a long-term basis for investors interested in exposure to big data analytics and specifically super-computing – a growing need for large enterprise and institutions all over the world

  • [By Peter Graham]

    The Q4 2016 earnings report for small capsupercomputer stock Cray Inc (NASDAQ: CRAY) is scheduled forafter the market closes onWednesday (February 8th). Back in 2012, Cray Inc was inour SmallCap Network Elite Opportunity (SCN EO) portfolioasa potentially goodlow risk longer-term play as shares were trading at the $12 level and eventually hit $40+ per share before coming back down to earth last year.

  • [By Giulio Prisco]

    Microsoft (NSDQ:MSFT), supercomputer maker Cray (NSDQ:CRAY), and the Swiss National Supercomputing Centre (CSCS), a world-class scientific computing center, announced the results of a deep learning collaboration that expands the horizons of running Artificial Intelligence (AI), Machine Learning (ML), and in particular Deep Learning (an especially promising branch of ML) applications, using Microsoft software and Cray supercomputers.

Top 5 Tech Stocks To Invest In Right Now: Glu Mobile Inc.(GLUU)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap mobile game stock Glu Mobile Inc (NASDAQ: GLUU) reportedQ2 2017 earnings after the market closed on Tuesday. Revenue grew 42% year over year to $68.7 million while bookingsincreased 62% to$82.5 million (whichexceed high end of guidance) and Design Home peaked as the#17 top grossing game on U.S. App Store for iPhone. The net loss was $23.568 million versus a net loss of $17.949 million. The Company also raised 2017 full year bookings guidance to a range of $307 million to $312 million.

  • [By Harsh Chauhan]

    Mobile gaming specialist Glu Mobile’s (NASDAQ:GLUU) net loss almost tripled in the first quarter despite a slight jump in revenue from the prior-year period. Its adjusted net loss of $0.15 per share was more than twice than Wall Street’s expectations of a $0.07-per-share loss.

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc largely moving sideways for the pastthree years or sowhile remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) has underperformed andlarge capActivision Blizzard continues to have a good run:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap mobile game stock Glu Mobile Inc (NASDAQ: GLUU)is scheduled for after the market closes onWednesday (February 8). In the past, our SmallCap Network Elite Opportunity (SCN EO) portfolio had open positions in other mobile game stocks with our SCN EO newsletter notingin August 2015 before that summers market meltdown:

Top 5 Tech Stocks To Invest In Right Now: ADTRAN Inc.(ADTN)

Advisors’ Opinion:

  • [By Monica Gerson]

    ADTRAN, Inc. (NASDAQ: ADTN) is projected to post its quarterly earnings at $0.08 per share on revenue of $141.07 million.

    Layne Christensen Company (NASDAQ: LAYN) is estimated to post a quarterly loss at $0.35 per share on revenue of $156.10 million.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 5 Tech Stocks To Invest In Right Now: RELM Wireless Corporation(RWC)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting small cap wireless communications manufacturer RELM Wireless Corporation (NYSEMKT: RWC):

Top 5 Tech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

Leave a Reply

Your email address will not be published. Required fields are marked *